Register for our free email digests:
Clovis Oncology Inc.
www.clovisoncology.com
Latest From Clovis Oncology Inc.
New CEO At MorphoSys Seeking Partner For ‘CAR-T Killer’ Lymphoma Drug
Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.
Lynparza Poised To Bring Targeted Therapy To Prostate Cancer
The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.
Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen
Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
Company Information
- Industry
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Clovis Oncology Inc.
- Senior Management
-
Patrick Mahaffy, Pres. & CEO
Dan Muehl, EVP, Fin.
Lindsey Rolfe, EVP, Clin. & Preclinical & Dev. & CMO - Contact Info
-
Clovis Oncology Inc.
Phone: (303) 625-5000
5500 Flatiron Parkway
Boulder, CO 80301
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice